Similitudes, traitements émergents et fardeau des maladies à lymphocytes T auxiliaires de type 2

Auteurs-es

  • Hermenio Lima, MD, PhD

Résumé

Né en 470 avant J.-C., Socrate était un philosophe de la Grèce antique considéré comme le premier philosophe de la morale, et le fondateur de la pensée éthique occidentale. Selon Platon, les contemporains de Socrate l’appelaient atopos, qui veut généralement dire « bizarre » ou « absurde », mais qui signifie littéralement « déplacé », « sans lieu » ou insaisissable pour ses pensées et idées nuancées. Et 2300 ans plus tard, le terme « atopie » désigne un ensemble de maladies atopiques : dermatite atopique (DA), asthme allergique (AA), rhume des foins, allergie alimentaire et rhinite allergique (RA).  

À la fin du XIXe siècle, les scientifiques ont remarqué que les réponses immunitaires provoquent des réactions indésirables dans des cas précis. Le concept selon lequel des réponses immunitaires sont à l’origine de certaines maladies semblait inconciliable avec celui de la fonction protectrice de l’immunité; c’est pourquoi ces maladies ont été appelées « réactions d’hypersensibilité ». Chez l’humain, certaines maladies appartenant au groupe des réactions d’hypersensibilité, aujourd’hui appelées allergies, ont finalement été classées au début du XXe siècle. 

Biographie de l'auteur-e

Hermenio Lima, MD, PhD

Dr. Hermenio Lima is a Clinical Immunologist and Dermatologist with a Ph.D. in Immunology focusing on skin disease immunoregulation from Harvard University. He is the director of the recently created Lima’s Excellence in Allergy and Dermatology (LEADER) Research. He is the Principal Investigator (PI) of multiple clinical and basic research, mainly on Atopic Dermatitis, Urticaria and Psoriasis. He created an Urticaria Centers of Reference and Excellence (UCARE) at his research facility. He is also an Associate Professor at the Divisions of Clinical Immunology and Dermatology and the Director at Division of Dermatology, Department of Medicine, Michael G. DeGroote School of Medicine McMaster University.

Références

Kennerly M. Socrates Ex Situ. Advances in the History of Rhetoric. 2017;20(2):196-208. doi:10.1080/15362426.2017.1327278

Aw M, Penn J, Gauvreau GM, Lima H, Sehmi R. Atopic March: Collegium Internationale Allergologicum Update 2020. Review. International Archives of Allergy and Immunology. 2020;181(1):1-10. doi:10.1159/000502958

Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. The Journal of Immunology. 1986;136(7):2348- 2357.

Walker JA, McKenzie ANJ. TH2 cell development and function. Nature Reviews Immunology. 2018;18(2):121-133. doi:10.1038/nri.2017.118

Shulman ST. Clemens von Pirquet: A Remarkable Life and Career. Journal of the Pediatric Infectious Diseases Society. 2016:piw063. doi:10.1093/jpids/piw063

Stark JM, Tibbitt CA, Coquet JM. The Metabolic Requirements of Th2 Cell Differentiation. Frontiers in Immunology. 2019;10 doi:10.3389/fimmu.2019.02318

Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387:1109-22. doi:10.1016/S0140-6736(15)00149-X

Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2019. Available from: https://ginasthma.org.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease: 2019 report. Nov 2018. Available from: https://goldcopd.org/archived-reports.

Hill DA, Spergel JM. The immunologic mechanisms of eosinophilic esophagitis. Curr Allergy Asthma Rep. 2016 Feb;16(2):9. doi:10.1007/s11882-015-0592-3

Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017 Jan 24;12:331-357. doi:10.1146/annurev-pathol-052016-100401

Bertschi NL, Bazzini C, Schlapbach C. The Concept of Pathogenic TH2 Cells: Collegium Internationale Allergologicum Update 2021. International Archives of Allergy and Immunology. 2021;182(5):365-380. doi:10.1159/000515144

Williamson PA, Vaidyanathan S, Clearie K, Barnes M, Lipworth BJ. Airway dysfunction in nasal polyposis: a spectrum of asthmatic disease? Clinical & Experimental Allergy. 2011;41(10):1379-1385. doi:10.1111/j.1365-2222.2011.03793.x

Zhang N, Van Zele T, Perez-Novo C, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol. 2008;122(5):961-968. doi:10.1016/j.jaci.2008.07.008

Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel- group phase 3 trials. Lancet. 2019 Nov 2;394(10209):1638-50. doi:10.1016/S0140-6736(19)31881-1

Seumois G, Ramírez-Suástegui C, Schmiedel BJ, et al. Single-cell transcriptomic analysis of allergen-specific T cells in allergy and asthma. Science Immunology. 2020;5(48):eaba6087. doi:10.1126/sciimmunol.aba6087

Corren J. New Targeted Therapies for Uncontrolled Asthma. J Allergy Clin Immunol. 2019;7(5):1394-1403. doi:10.1016/j. jaip.2019.03.022

Islam SA, Chang DS, Colvin RA, et al. Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ TH2 cells. Nature Immunology. 2011;12(2):167-177. doi:10.1038/ni.1984

Hijnen D, De Bruin-Weller M, Oosting B, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol. 2004;113:334-40.

Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nature Reviews Disease Primers. 2018;4(1). doi:10.1038/s41572-018-0001-z

Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal of the American Academy of Dermatology. 2017;76(4):736- 744. doi:10.1016/j.jaad.2016.12.005

AJMC Perspectives. Evolving Treatment Strategies in Type 2 Inflammatory Disease. Perspectives in Type 2 Inflammation. Jun 2019. Available from: https://www.ajmc.com/view/evolving-treatment-strategies-in-type-2-inflammatory-disease.

Mitson-Salazar A, Prussin C. Pathogenic Effector Th2 Cells in Allergic Eosinophilic Inflammatory Disease. Front Med. 2017;4. doi:10.3389/fmed.2017.00165

Bruton K, Spill P, Vohra S, et al. Interrupting reactivation of immunologic memory diverts the allergic response and prevents anaphylaxis. J Allergy Clin Immunol. 2021;147(4):1381-1392. doi:10.1016/j.jaci.2020.11.042

Eskian M, Khorasanizadeh M, Assa’Ad AH, Rezaei N. Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis. Clin Rev Allergy Immunol. 2018;55(1):88-98. doi:10.1007/s12016-017-8659-7

Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology. 2020;158(1):111-122.e10. doi:10.1053/j.gastro.2019.09.042

Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy. 2004 Apr;34(4):520-6. doi:10.1111/j.1365-2222.2004.1935.x

Paller A, Jaworski JC, Simpson EL, et al. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. Am J Clin Dermatol. 2018;19(6):821-838. doi:10.1007/s40257-018-0383-4

Irvine AD, Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner’s guide. Br J Dermatol. 2019 Nov;181(5):895-906. doi:10.1111/bjd.17766

Belgrave DCM, Granell R, Simpson A, Guiver J, Bishop C, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014 Oct 21;11(10):e1001748. doi:10.1371/journal.pmed.1001748

Bergmann RL, Wahn U, Bergmann KE. The allergy march: from food to pollen. Environmental Toxicology and Pharmacology. 1997;4(1-2):79-83. doi:10.1016/ s1382-6689(97)10045-x

Similitudes, traitements émergents et fardeau des maladies à lymphocytes T auxiliaires de type 2

Téléchargements

Publié

2023-07-05

Comment citer

1.
Similitudes, traitements émergents et fardeau des maladies à lymphocytes T auxiliaires de type 2. Can Allergy Immunol Today [Internet]. 5 juill. 2023 [cité 20 mars 2026];1(s11):3–7. Disponible à: https://canadianallergyandimmunologytoday.com/article/view/44

Numéro

Rubrique

Articles

Comment citer

1.
Similitudes, traitements émergents et fardeau des maladies à lymphocytes T auxiliaires de type 2. Can Allergy Immunol Today [Internet]. 5 juill. 2023 [cité 20 mars 2026];1(s11):3–7. Disponible à: https://canadianallergyandimmunologytoday.com/article/view/44

Articles les plus lus du,de la,des même-s auteur-e-s